Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 7/20 | 0.54 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.54 |
| ▸ | PARP1 | P09874 | 3/20 | 0.50 |
| ▸ | PARP2 | Q9UGN5 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | GRM5 | P41594 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ALOX15B | O15296 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14638193 | 0.89 | TNKS (0.54) | TNKSTNKS2PARP1PARP2MAPT | |
| SCHEMBL14638388 | 0.86 | TNKS (0.53) | TNKSTNKS2PARP1PARP2MAPT | |
| SCHEMBL14638042 | 0.85 | POLB (0.61) | TNKSTNKS2PARP1PARP2MAPT | |
| SCHEMBL14637530 | 0.84 | MAPT (0.55) | TNKSTNKS2PARP1PARP2MAPT | |
| SCHEMBL12049758 | 0.79 | GRM5 (0.54) | MAPTGRM5CA1CA2POLB | |
| SCHEMBL18133045 | 0.78 | CA1 (0.51) | TNKSTNKS2PARP1PARP2MAPT | |
| SCHEMBL27968848 | 0.76 | MAPT (0.50) | TNKSTNKS2PARP1PARP2MAPT | |
| SCHEMBL12026462 | 0.75 | HTR4 (0.54) | MAPTGRM5CA1CA2POLB | |
| SCHEMBL1653095 | 0.75 | SMN1; SMN2 (0.56) | TNKSPARP1PARP2MAPTHDAC3 | |
| SCHEMBL14638104 | 0.75 | SMN1; SMN2 (0.53) | TNKSTNKS2PARP1PARP2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181266-B2 | 2-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitors | NOVARTIS AG (CH) | 2015-11-10 | — | — | US | disclosed |
| US-9181266-B2 | 2-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitors | NOVARTIS AG (CH) | 2015-11-10 | — | — | US | disclosed |
| US-9181266-B2 | 2-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitors | NOVARTIS AG (CH) | 2015-11-10 | — | — | US | disclosed |
| EP-2731942-B1 | NOVEL 2-PIPERIDIN-1-YL-ACETAMIDE COMPOUNDS FOR USE AS TANKYRASE INHIBITORS | NOVARTIS AG (CH) | 2015-09-23 | — | — | EP | disclosed |
| EP-2731942-B1 | NOVEL 2-PIPERIDIN-1-YL-ACETAMIDE COMPOUNDS FOR USE AS TANKYRASE INHIBITORS | NOVARTIS AG (CH) | 2015-09-23 | — | — | EP | disclosed |
| US-20150025070-A1 | NOVEL 2-PIPERIDIN-1-YL-ACETAMIDE COMPOUNDS FOR USE AS TANKYRASE INHIBITORS | NOVARTIS AG (CH) | 2015-01-22 | — | — | US | disclosed |
| US-20150025070-A1 | NOVEL 2-PIPERIDIN-1-YL-ACETAMIDE COMPOUNDS FOR USE AS TANKYRASE INHIBITORS | NOVARTIS AG (CH) | 2015-01-22 | — | — | US | disclosed |
| US-20150025070-A1 | NOVEL 2-PIPERIDIN-1-YL-ACETAMIDE COMPOUNDS FOR USE AS TANKYRASE INHIBITORS | NOVARTIS AG (CH) | 2015-01-22 | — | — | US | disclosed |
| EP-2731942-A1 | NOVEL 2-PIPERIDIN-1-YL-ACETAMIDE COMPOUNDS FOR USE AS TANKYRASE INHIBITORS | Novartis AG (CH) | 2014-05-21 | — | — | EP | disclosed |
| WO-2013012723-A1 | NOVEL 2-PIPERIDIN-1-YL-ACETAMIDE COMPOUNDS FOR USE AS TANKYRASE INHIBITORS | NOVARTIS AG (CH) | 2013-01-24 | — | — | WO | disclosed |
| WO-2013012723-A1 | NOVEL 2-PIPERIDIN-1-YL-ACETAMIDE COMPOUNDS FOR USE AS TANKYRASE INHIBITORS | NOVARTIS AG (CH) | 2013-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025070-A1 | NOVEL 2-PIPERIDIN-1-YL-ACETAMIDE COMPOUNDS FOR USE AS TANKYRASE INHIBITORS | WNT1, TNKS1BP1, TNKS | TNKS 3/4885TNKS2 4/4885PARP1 154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.